Technology
Medtronic Announces Positive Real-World Registry Results for Sphere-9 Catheter and PulseSelect PFA System
Medtronic presented real-world registry results at APHRS 2026 for the Sphere-9 catheter and PulseSelect PFA system, showing low complication rates and high acute success, with expanded VT evidence.
Published · Updated · Source: Surgical Robotics Technology · AI translation
IllustrationMedtronic presented global real-world registry analyses of the Affera Mapping and Ablation System with the Sphere-9 catheter and the PulseSelect Pulsed Field Ablation (PFA) System at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting. The APEX registry analysis included 1,050 patients with atrial fibrillation (AFib) across 28 global sites; the major complication rate was 1.1%, with no acute kidney injury, severe coronary spasm or phrenic nerve injury, and no significant difference between de novo and repeat ablation procedures. The REAL PULSE registry analysis included 1,160 AFib patients across 38 global sites, with a 100% acute success rate and a 0.09% acute major complication rate.
A separate European APEX registry analysis evaluated the Sphere-9 catheter in 46 patients with ischemic and non-ischemic sustained ventricular tachycardia (VT), showing an 87% acute success rate and an estimated six-month freedom from VT recurrence of 75%, with no significant difference in long-term freedom from arrhythmia recurrence between ischemic and non-ischemic cardiomyopathy patients; six major complications were reported in four patients. Sphere-9 is CE marked for VT and is investigational only and not approved for VT in the United States. This information comes from the original source and was organized by AI.
Read the original source